Skip to content

ActiPatch Plantar Fasciitis Clinical Trial

Continuous Low Energy Pulsed Radio Frequency Electromagnetic Field Therapy for the Treatment of Plantar Fasciopathy

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01431066
Enrollment
28
Registered
2011-09-09
Start date
2011-12-31
Completion date
2013-07-31
Last updated
2014-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fasciitis, Plantar Fasciopathy

Brief summary

Plantar fasciopathy is a chronic condition affecting both sedentary populations, individuals in the workplace who must stand for prolonged periods of time, and athletes. It can be disabling. There is no single accepted treatment course that is recommended in the literature. The use of pulsed radio-frequency electromagnetic (PRFE) devices has been proposed as a treatment option in chronic soft-tissue injury due to its ability to reduce pain and inflammation. The proposed study will investigate the efficacy of the use of a PRFE device for the treatment of chronic heel pain using a double blind randomized placebo controlled design study.

Interventions

DEVICESham pulsed radio-frequency electromagnetic device

Disabled PRFE device

DEVICEActiPatch PRFE Device

Actipatch PRFE device

Sponsors

BioElectronics Corporation
CollaboratorINDUSTRY
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* All patients with diagnosis of plantar fasciitis agreeing to participate * Over 18 years old * Able to wear unit and keep data up-to-date records of use * Agree to forgo additional treatments during the study period

Exclusion criteria

* Patients who have refused, are unable to give or have withdrawn consent * Patients with heel pain present less than 3 months

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale (VAS) for pain4 Weeks Follow-up

Secondary

MeasureTime frame
Visual analog scale for pain26 weeks
Foot and ankle disability index26 weeks
Tegner activity scale26 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026